Oxford BioDynamics (OBD), a biotechnology company specializing in 3D genomic biomarker technology, has entered into a strategic partnership with Google Cloud to enhance its analytical capabilities and accelerate precision medicine applications. The collaboration leverages Google Cloud's infrastructure to scale OBD's proprietary EpiSwitch platform, enabling high-throughput, AI-powered 3D genomic analytics for pharmaceutical and biotechnology partners.
Enhanced Analytical Framework Through Cloud Computing
The partnership centers on expanding OBD's analytical framework by utilizing Google Cloud's computing infrastructure. This collaboration will enable the biotech firm to scale its proprietary EpiSwitch knowledge base and analytical tools, delivering enhanced genomic analytics capabilities in a secure and efficient cloud environment.
Google Cloud will provide comprehensive support through cloud computing resources, allowing OBD to enhance its existing technological infrastructure. The resources will support the deployment of containerized applications, integration with Google Cloud's AI/ML tools, and the creation of secure, scalable data processing pipelines designed to meet healthcare compliance standards.
Strategic Vision for Precision Medicine
Iain Ross, OBD's Executive Chairman, emphasized the transformative potential of the collaboration. "Working with Google Cloud allows OBD to rapidly scale its analytical capabilities, bringing it closer to delivering precision 3D genomics insights in real time," Ross stated. He added, "We are excited to develop a powerful and interoperable platform that aligns with the future of cloud-native biomedical research."
The partnership represents part of OBD's broader digital transformation strategy, aimed at facilitating faster access to predictive genomic insights for drug development and diagnostics applications.
EpiSwitch Platform Technology
OBD's EpiSwitch platform serves as the foundation for this enhanced analytical capability. The platform is a clinically validated technology that identifies regulatory changes in 3D genome architecture, which can be used to detect disease signatures and aid in target development. The cloud-based enhancement will make this platform more accessible to industry partners while paving the way for future commercialization opportunities.
Global Infrastructure and Scalability
The collaboration leverages Google Cloud's global infrastructure to enable broader accessibility and enhanced collaboration capabilities. Ross noted that "Google Cloud's global infrastructure allows us to share insights faster, collaborate more easily with our partners, and bring our predictive genomic tools into clinics and labs around the world - at scale."
The partnership positions OBD to deliver real-time genomic insights through a cloud-native approach, potentially transforming how pharmaceutical and biotechnology companies access and utilize 3D genomic analytics for precision medicine applications.
